annual general meeting review, page-12

Okay, just come back from the beach and have read your feedback, in order....

Ralom - No, or perhaps I missed him.

Digga73 - Hernia progress not really mentioned other then that it is a massive market which we all new anyway. The impression I got was that now all the company's attention is focused on launching Cardiocel in Europe and FDA approval, HSV-2 Phase 1 progress and results.... Hernia later on.

Russ - Didn't make me feel good or bad and was the answer I was expecting as I imagine there's some degree of confidentiality attached at the early stages. When Lee said he was unsure I interpreted that from his body language to mean he new although wasn't going to tell us at the meeting. All things in time.

Lexcorp - As I already had got two questions in I didn't want to ask any more and Chris Catlow looked like he wanted to shut the meeting down as by then it had gone for an hour and a half which I think was their time limit. Although see my answer to Digga73 above, that is where the company's main focus is at the moment. Perhaps one to email and ask Julian??

* It was also mentioned that there had now been 80 patients successfully treated with the Cardiocel patch (this is excluding the 30 who took part in the Phase II trial 5 years back.)